4D Molecular Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$12.28

+2.76%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 02:37 IST · A quote does not mean the product is available to trade on your account.

Day's open: $12.36
Previous close: $11.95
Volume: 764,668
Day's high: $12.44
Day's low: $11.51

In brief

4D Molecular Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $678M.
Its shares closed at $12.28 on 4 Nov 2026, up 14.2% over the past year.
From India you can buy FDMT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy 4D Molecular Therapeutics, Inc. (FDMT) shares from India?

Yes. Indian residents can invest in the US stock market under the Reserve Bank of India's Liberalised Remittance Scheme (LRS), which lets a resident individual remit up to USD 250,000 per financial year, across all permitted purposes combined. US-listed stocks and ETFs are a permitted investment under the LRS. You are solely responsible for ensuring your remittances comply with the LRS annual limit, the applicable Tax Collected at Source (TCS) rules, and all reporting requirements, including Schedule FA in your income-tax return.

Do I need the price of a whole FDMT share to invest?

Yes. You can buy fractional shares, which lets you invest a fixed rupee/dollar amount even in high-priced stocks. For example, if one share trades at USD 1,000 and you invest USD 100, you receive 0.1 of a share.

How much can I invest in US stocks in a year?

Under the LRS, an Indian resident can remit up to USD 250,000 per financial year (April to March) across all permitted purposes combined, from their own funds. This is a per-individual limit set by the RBI.

Can I trade FDMT options or futures?

No. Under RBI / FEMA rules, the LRS does not permit margin trading or speculative instruments such as futures, options, or other derivatives. Your US account is a cash account, not a derivatives and margin account.

Insights

Quotes run fifteen minutes behind.

12.0 days to cover short interest
11.5M shares were sold short at the 15 Oct 2026 settlement, 20.9% of the 55.2M shares outstanding; covering them would take 12.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
In line with SPY, behind its sector fund XLV over 1 year
1 month: −2.2% (SPY −1.6%, XLV +13.5%). 3 months: +19.5% (SPY −0.4%, XLV +15.5%). 1 year: +14.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: FDMT, SPY and XLV · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $12.28 was 9.0% below its 50-day average ($13.49) and 12.3% above its 200-day average ($10.94). It has closed above the 200-day for 69 sessions, since 30 Jul 2026. The 50-day average crossed above the 200-day on 22 Aug 2025, 302 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
53% of the way up its 52-week range
Closed at $12.28 on 4 Nov 2026: 27.5% below the 52-week high of $16.93 (19 Aug 2026) and 76.4% above the low of $6.96 (5 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.2%

6 months+17.9%

1 year+14.2%

5 years−49.9%

Newswire

About

4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).

Website

Notable moves

August 1, 2025
+42.67%
February 5, 2024
+84.62%
November 15, 2022
+38.55%

4D Molecular Therapeutics, Inc.

XNASHealth care

Last traded price · USD

$12.28

+2.76%Market closed

Delayed 15 minutes · Source: ViewTrade · 5 Nov 2026, 02:37 IST · A quote does not mean the product is available to trade on your account.

Day's open: $12.36
Previous close: $11.95
Volume: 764,668
Day's high: $12.44
Day's low: $11.51

In brief

4D Molecular Therapeutics, Inc. is a health care company listed on Nasdaq, valued at about $678M.
Its shares closed at $12.28 on 4 Nov 2026, up 14.2% over the past year.
From India you can buy FDMT in US dollars under the RBI's Liberalised Remittance Scheme, including a fraction of one share. See what it costs

Questions investors ask

Can I buy 4D Molecular Therapeutics, Inc. (FDMT) shares from India?

Do I need the price of a whole FDMT share to invest?

How much can I invest in US stocks in a year?

Can I trade FDMT options or futures?

Insights

Quotes run fifteen minutes behind.

12.0 days to cover short interest
11.5M shares were sold short at the 15 Oct 2026 settlement, 20.9% of the 55.2M shares outstanding; covering them would take 12.0 days of average volume. Short interest is reported twice a month, on a lag.
Exchange short-interest filing · as of 15 Oct 2026
In line with SPY, behind its sector fund XLV over 1 year
1 month: −2.2% (SPY −1.6%, XLV +13.5%). 3 months: +19.5% (SPY −0.4%, XLV +15.5%). 1 year: +14.2% (SPY +13.6%, XLV +30.7%). Price change to the 4 Nov 2026 close; dividends excluded.
Daily closes, split-adjusted: FDMT, SPY and XLV · as of 4 Nov 2026
Below its 50-day average, above its 200-day
The 4 Nov 2026 close of $12.28 was 9.0% below its 50-day average ($13.49) and 12.3% above its 200-day average ($10.94). It has closed above the 200-day for 69 sessions, since 30 Jul 2026. The 50-day average crossed above the 200-day on 22 Aug 2025, 302 sessions ago.
Daily closes, split-adjusted; 50- and 200-session simple averages · as of 4 Nov 2026
53% of the way up its 52-week range
Closed at $12.28 on 4 Nov 2026: 27.5% below the 52-week high of $16.93 (19 Aug 2026) and 76.4% above the low of $6.96 (5 Jan 2026).
Daily price bars, split-adjusted · as of 4 Nov 2026

Returns

Price return, split-adjusted

At the 4 Nov 2026 close

1 month−2.2%

6 months+17.9%

1 year+14.2%

5 years−49.9%

Newswire

About

Website

Notable moves

August 1, 2025
+42.67%
February 5, 2024
+84.62%
November 15, 2022
+38.55%

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. in brief

12.0 days to cover short interest

In line with SPY, behind its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

53% of the way up its 52-week range

4D Molecular Therapeutics, Inc.

4D Molecular Therapeutics, Inc. in brief

12.0 days to cover short interest

In line with SPY, behind its sector fund XLV over 1 year

Below its 50-day average, above its 200-day

53% of the way up its 52-week range